Fenretinide

• Description:

  Fenretinide (4-HPR) is a synthetic retinoid deriverative, binding to the retinoic acid receptors (RAR) at concentrations necessary to induce cell death.

• Product Name Alternative:

  4-HPR; ISLA-101

• UNSPSC:

  12352005

• Hazard Statement:

  H302+H312+H332, H315, H319, H335, H360

• Target:

  Autophagy; RAR/RXR

• Type:

  Reference compound

• Related Pathways:

  Autophagy; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Fenretinide.html

• Purity:

  99.15

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  CC(/C=C/C=C(/C=C/C1=C(CCCC(C)1C)C)C)=C\C(NC2=CC=C(O)C=C2)=O

• Molecular Formula:

  C26H33NO2

• Molecular Weight:

  391.55

• Precautions:

  H302+H312+H332, H315, H319, H335, H360

• References & Citations:

  [1]Apraiz, Aintzane., et al. Dihydroceramide accumulation and reactive oxygen species are distinct and nonessential events in 4-HPR-mediated leukemia cell death. Biochemistry and Cell Biology (2012), 90 (2), 209-223.|[2]Bikman, Benjamin T., et al. Fenretinide Prevents Lipid-induced Insulin Resistance by Blocking Ceramide Biosynthesis. Journal of Biological Chemistry (2012), 287 (21), 17426-17437.|[3]Cooper JP, et al. Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure. Br J Pharmacol. 2011 Jul;163 (6) :1263-75.|[4]Golubkov V, et al. Action of fenretinide (4-HPR) on ovarian cancer and endothelial cells. Anticancer Res. 2005 Jan-Feb;25 (1A) :249-53.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [65646-68-6]